New cause of brain defects in tuberous sclerosis complex
A new molecular pathway that inhibits the myelination of neurons in the brains of patients with the rare genetic disorder tuberous sclerosis complex (TSC) has been discovered by researchers. The study suggests new ways to treat some of the neurological symptoms associated with TSC, including autism and epilepsy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 9, 2017 Category: Science Source Type: news
Novartis says Votubia receives EU approval for new indication
ZURICH (Reuters) - Novartis has broadened the indications for its Votubia drug, the company said on Tuesday, when the European Union approved its use to treat refractory partial-onset seizures in patients with tuberous sclerosis complex. (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Findings in tuberous sclerosis complex on the role of inflammation and epilepsy
(US Department of Defense Congressionally Directed Medical Research Programs) Dr. Wong focused on ECG treatment in the mice and found that treatment did minimally correct some of the brain tissue abnormalities seen in the mouse model, but, more importantly, there was a small decrease in seizure development and slightly improved survival in these mice. Dr. Wong and his laboratory have provided a proof-of-concept preclinical study suggesting that anti-inflammatory treatment could be a potential therapy for epilepsy in TSC patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 19, 2016 Category: Global & Universal Source Type: news
Sirolimus Gel for Tuberous Sclerosis Facial Angiofibromas Sirolimus Gel for Tuberous Sclerosis Facial Angiofibromas
A topical sirolimus gel is safe and effective for treating facial angiofibromas in patients with tuberous sclerosis complex (TSC), Japanese researchers report.Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 23, 2016 Category: Dermatology Tags: Hematology-Oncology News Source Type: news
EXIST-3: Everolimus Decreases Seizures in Tuberous Sclerosis EXIST-3: Everolimus Decreases Seizures in Tuberous Sclerosis
Calling the study ' ground-breaking, ' one expert says the results ' nail down ' important issues involved in targeting tuberous sclerosis seizures ' with a rational, pathophysiological approach. 'Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 10, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Drug reduces seizure frequency in children with tuberous sclerosis complex
(Cincinnati Children's Hospital Medical Center) In an international study, the drug everolimus has been shown to significantly reduce the frequency of seizures in patients with treatment-resistant epilepsy and tuberous sclerosis complex (TSC) -- a genetic disease that causes malformations and tumors in the brain and other vital organs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 6, 2016 Category: Cancer & Oncology Source Type: news
Research note: Yale team provides new insight into intractable epilepsy
One of the major causes of intractable epilepsy is a malformation of brain development that occurs in individuals with focal cortical dysplasia or tuberous sclerosis complex. These malformations are marked by misplaced and abnormally large neurons in focal cortical brain regions. However, a Yale team led by Angelique Bordey and Lawrence S. Hsieh developed a new mouse model of focal cortical malformation that showed neuronal misplacement is not required to trigger seizures. Instead, large misshapen neurons by themselves can generate seizures, according to the study published June 1 in the journal Nature Communications. The ...
Source: Yale Science and Health News - June 2, 2016 Category: Universities & Medical Training Tags: Yale News Source Type: news
Everolimus May Have Activity in Seizure Disorder
(MedPage Today) -- Drug reduced seizure frequency in tuberous sclerosis compared with placebo (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - April 22, 2016 Category: Journals (General) Source Type: news
Everolimus Data for Seizures in Tuberous Sclerosis 'Exciting'Everolimus Data for Seizures in Tuberous Sclerosis 'Exciting'
The new results may open the door to eventually being able to treat epilepsy, not just seizures, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 21, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
GW Pharmaceuticals initiates Phase 3 study of Epidiolex for TSC disorder
GW Pharmaceuticals has started a Phase 3 clinical trial of Epidiolex as an adjunctive therapy for treatment of seizures related to tuberous sclerosis complex (TSC), a rare genetic disorder where the most common symptom is epilepsy. (Source: Drug Development Technology)
Source: Drug Development Technology - April 11, 2016 Category: Pharmaceuticals Source Type: news
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
LONDON, April 11, 2016 -- (Healthcare Sales & Marketing Network) -- GW Pharmaceuticals plc (GWPH) (GWP.L) (GW or the Company), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ca... Biopharmaceuticals, NeurologyGW Pharmaceuticals, Epidiolex, cannabidiol, Tuberous Sclerosis Complex (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2016 Category: Pharmaceuticals Source Type: news
Cancer study is 'paradigm shift' in cause of tumor formation
A gene that may provide a new source of potential drug targets for tumors that arise in pulmonary tuberous sclerosis complex (TSC) has been found by a pair of investigators. The discovery may change what is known about tumor formation and help to slow or halt tumor growth, therefore having broader implications in cancer research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 17, 2016 Category: Science Source Type: news
Blanket forts, healthy hearts and life: What our families are thankful for
When parents and children first arrive at our front door — no matter why or from where they come — they forever become part of our extended family.
On this Thanksgiving, just like the 47 million others who are traveling to see loved ones, we too packed up the car and drove to visit 11 of the families who have stayed with us at Boston Children’s over the years. We wanted to find out what they were most thankful for and what makes this season special to them.
Thank you to the families of Ella S., Julian, Ella D., Addison, Callum, Nora, Avery, Jace, Molly, Charlotte, Murphy and Robbie for welcoming us into your hom...
Source: Thrive, Children's Hospital Boston - November 26, 2015 Category: Pediatrics Authors: Jenny Fernandez Tags: All posts Thanksgving Source Type: news
Everolimus Results Improve for SEGA in Tuberous Sclerosis Everolimus Results Improve for SEGA in Tuberous Sclerosis
The EXIST-1 extension trial shows that rates of response to treatment with everolimus improved after 4 years in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 2, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
For children with rare genetic disorder, more extensive epilepsy surgery yields better seizure control
(Wolters Kluwer Health) Children with the genetic disorder tuberous sclerosis complex often need epilepsy surgery for severe, uncontrollable seizures. A new study finds that seizure control is improved for patients undergoing more extensive surgery, reports the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2015 Category: Global & Universal Source Type: news
